The New York Genome Center has a nice round up post on Clinical Genomics talks from day two of the Advances in Genome Biology and Technology conference. You can see all their posts from the meeting on their website.

The FDA has approved TDM-1 for breast cancer, according to coverage from Reuters. Here is a brief item from Forbes about the drug and its cost, A Triumph in Breast Cancer–And Another Expensive Drug. (A number of people on Twitter have commented that the brand name is Kadcyla a bit close to Kalydeco, a drug used in the treatment of cystic fibrosis.)

On Thursday, the NIH announced a new US policy for research with potentially risky subjects requiring stricter controls, such as H5N1.  The LA Times has coverage, and this post from the Nature News Blog includes a number of helpful links, as well as official opportunities for public comment on the policy related to this type of research, referred to as “dual-use research of concern”.

The Washington Post WonkBlog explains a new regulation on how insurance companies must cover colonoscopies under the Affordable Care Act.

Over the past few weeks…

This past Friday, news began circulating that the Obama administration was considering supporting publishers in their appeal of the Georgia State University e-reserves case which had found that electronic reserves were a form of fair use, here is a post from TechDirt. About the news in the case Nancy Simms, Copyright Librarian at the University of Minnesota Libraries, wrote What is the government’s interest in copyright? Not that of the public. Kevin Smith, Duke University Scholarly Communications officer also wrote about the case, outlining what he feels the library community needs to know in Law and Politics in the GSU Case.

Cool Tools U blogged about ImpactStory, a new open source tool that allows researchers to track and share data about their output and impact across various  media from  journal articles and data sets to blog posts and YouTube videos.

GSK has joined All Trials pledging to support the campaign and open the information from their drug trails. Here is Ben Goldacher’s post.

Deborah Blum has a post called A Takedown at Retraction Watch on the Knight Science Journalism Tracker explaining the strange case of posts being removed from Retraction Watch by WordPress administrators following claims of plagiarism.

Wondering about tools for evaluating and assessing the quality of published resources? Check out the Grade Project.

Catching my eye this week…

Alison Aldrich has written an in-depth review of Docphin over at Krafty Librarian.

NPR’s Shots blog has a piece about loopholes in GINA (the Genetic Information Nondiscrimination Act), which allow some companies to discriminate based on people’s genes.

A piece on a realistic long-term care solution now that the ACA provisions have been overturned.